Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Catalyst Pharmaceuticals (CPRX) EPS (Weighted Average and Diluted) (2018 - 2025)

Catalyst Pharmaceuticals (CPRX) has disclosed EPS (Weighted Average and Diluted) for 8 consecutive years, with $0.4 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EPS (Weighted Average and Diluted) fell 9.09% year-over-year to $0.4, compared with a TTM value of $1.68 through Dec 2025, up 28.24%, and an annual FY2025 reading of $1.68, up 28.24% over the prior year.
  • EPS (Weighted Average and Diluted) was $0.4 for Q4 2025 at Catalyst Pharmaceuticals, down from $0.42 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $0.45 in Q1 2025 and bottomed at -$0.29 in Q3 2023.
  • Average EPS (Weighted Average and Diluted) over 5 years is $0.24, with a median of $0.24 recorded in 2022.
  • The sharpest move saw EPS (Weighted Average and Diluted) tumbled 245.0% in 2023, then surged 220.69% in 2024.
  • Year by year, EPS (Weighted Average and Diluted) stood at $0.09 in 2021, then skyrocketed by 155.56% to $0.23 in 2022, then surged by 34.78% to $0.31 in 2023, then skyrocketed by 41.94% to $0.44 in 2024, then decreased by 9.09% to $0.4 in 2025.
  • Business Quant data shows EPS (Weighted Average and Diluted) for CPRX at $0.4 in Q4 2025, $0.42 in Q3 2025, and $0.41 in Q2 2025.